Dynavax Technologies Corporation Asset Resilience Ratio
Dynavax Technologies Corporation asset resilience ratio. Dynavax Technologies Corporation (DVAX) has an Asset Resilience Ratio of 51.51% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Dynavax Technologies Corporation to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Dynavax Technologies Corporation (2001–2024)
Asset resilience ratio of Dynavax Technologies Corporation from 2001 to 2024. This chart shows how Dynavax Technologies Corporation's Asset Resilience Ratio has changed over time. Read DVAX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Dynavax Technologies Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see DVAX total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $487.57 Million | 51.51% |
| Total Liquid Assets | $487.57 Million | 51.51% |
Asset Resilience Insights
- Very High Liquidity: Dynavax Technologies Corporation maintains exceptional liquid asset reserves at 51.51% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Dynavax Technologies Corporation Industry Peers by Asset Resilience Ratio
Compare Dynavax Technologies Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Dynavax Technologies Corporation Asset Resilience Ratio by Year (2001–2024)
Dynavax Technologies Corporation asset resilience ratio by year from 2001 to 2024. The table below shows the annual Asset Resilience Ratio data for Dynavax Technologies Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 62.66% | $617.95 Million | $986.26 Million | +3.28pp |
| 2023-12-31 | 59.37% | $592.02 Million | $997.10 Million | +16.53pp |
| 2022-12-31 | 42.85% | $422.39 Million | $985.85 Million | +32.28pp |
| 2021-12-31 | 10.56% | $109.76 Million | $1.04 Billion | -27.08pp |
| 2020-12-31 | 37.64% | $132.96 Million | $353.27 Million | -2.20pp |
| 2019-12-31 | 39.84% | $111.17 Million | $279.07 Million | -5.78pp |
| 2018-12-31 | 45.61% | $96.19 Million | $210.88 Million | -29.93pp |
| 2017-12-31 | 75.54% | $165.27 Million | $218.78 Million | +23.46pp |
| 2016-12-31 | 52.08% | $57.13 Million | $109.68 Million | -17.76pp |
| 2015-12-31 | 69.85% | $151.31 Million | $216.63 Million | +16.96pp |
| 2014-12-31 | 52.89% | $73.14 Million | $138.29 Million | -28.36pp |
| 2013-12-31 | 81.25% | $166.25 Million | $204.62 Million | -2.85pp |
| 2012-12-31 | 84.10% | $117.53 Million | $139.75 Million | +22.94pp |
| 2011-12-31 | 61.16% | $82.02 Million | $134.10 Million | +2.17pp |
| 2010-12-31 | 58.99% | $49.70 Million | $84.25 Million | +57.64pp |
| 2009-12-31 | 1.35% | $681.00K | $50.47 Million | -43.20pp |
| 2008-12-31 | 44.55% | $40.37 Million | $90.62 Million | +9.41pp |
| 2007-12-31 | 35.14% | $42.32 Million | $120.45 Million | -21.89pp |
| 2006-12-31 | 57.03% | $58.68 Million | $102.89 Million | -25.86pp |
| 2005-12-31 | 82.88% | $66.39 Million | $80.09 Million | +16.01pp |
| 2004-12-31 | 66.88% | $49.25 Million | $73.65 Million | +49.06pp |
| 2003-12-31 | 17.82% | $5.63 Million | $31.59 Million | -59.18pp |
| 2002-12-31 | 77.00% | $24.24 Million | $31.48 Million | +27.99pp |
| 2001-12-31 | 49.02% | $7.41 Million | $15.12 Million | -- |
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more